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In the present report, we serially measured the levels ofinterleukin-6 (IL-6) and
some acute-phase proteins (APP) in 61 lung cancer patients undergoing radio-
therapy in order to investigate the relationship between the response to the treat-
ment and the changes in parameters of systemic inflammatory response.
The patients were divided into two groups depending on the response to the
treatment. The first group (referred to as responders) comprised 32 patients with
stable disease, partial remission or total remission. Twenty-nine patients with
progression of the disease were included to the second group (referred to as
non-responders). Six patients died due to the lung cancer during the study. We
showed a decrease in IL-6 serum level and C-reactive protein (CRP) level in
responders but not in non-responders. However, the most interesting results
were obtained after retrospective analysis of the data of six deceased patients.
In these patients we observed an elevation ofIL-6 and CRP before the patients'
deaths.
Following the changes in acute-phase response and interleukin-6 serum levels
in lung cancer patients seems to be helpful in prognosis of the outcome of the
disease. Based on our data, we conclude that an elevation in IL-6 and/or CRP
level in patients with lung cancer may serve as an adverse prognostic factor.
INTRODUCTION
Acute-phase proteins (APP)c have been defined as those which plasma concentration
increases (positiveAPP) or decreases (negativeAPP) by 25 percent or more following tis-
sue injury or infection. Changes in APP are observed in inflammatory and autoimmune
diseases as well as in cancer. APPs are mainly synthesized and glycosylated by the liver.
Although at present, nine cytokines have been found capable of directly inducing acute-
phase proteins' production in the liver (i.e., IL-1, IL-6, IL-I1, TNF [tumor necrosis fac-
tor], interferon-gamma, LIF [leukemia inhibitory factor], TGF-beta [transforming growth
factor-beta], oncostatin M and CNTF [ciliary neurotrophic factor] [1-4]), IL-6 is a major
hepatocyte stimulator ofAPP synthesis [1, 5].
Interleukin-6 (IL-6) is a potent multifunctional protein. It is produced by many dif-
ferent cell types including T-cells, B-cells, monocytes, fibroblasts, chondrocytes, mesan-
gial cells, glial cells, endothelial cells, keratinocytes and certain tumor cells [1, 6].
However, monocytes/macrophages are predominantly responsible for IL-6 production.
IL-6 is considered to be a cytokine that plays a central role in the host-defense mecha-
nism. The biological activities of IL-6 have been shown to take part in the induction of
a To whom all correspondence should be addressed: Jan K. Lacki, M.D., Department of Clinical
Immunology and Allergy, K. Marcinkowski University of Medical Sciences, ul. Winogrady 144,
PL-61-626 Poznan, Poland. Tel: 48-61-528802; Fax: 48-61-524261.
c Abbreviations: APP, acute-phase proteins; CRP, C-reactive protein; ACT, alpha-I antichy-
motrypsin; AGP, alpha-I acid glycoprotein; IL-6, interleukin-6.
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B-lymphocytes to immunoglobulin synthesis, the activation and differentiation ofT-cells
and in the activation ofmegakaryocytes.
Contradictory data have been produced concerning the role of IL-6 in patients with
various malignancies. Antitumor capacities ofIL-6 were demonstrated in vitro and in vivo
in patients with breast cancer, lung cancer and some leukemia [7-9]. On the other hand,
IL-6 supports the growth of myeloma [10]. It has already reported that IL-6 and IL-6-
mediated systemic inflammatory response are related to hypermetabolism and cachexia in
lung cancer patients [11]. Finally, the elevated serum IL-6 levels are adverse prognostic
factor in kidney cancer patients [12].
In the present report, we serially measured the levels of IL-6 and some APP in lung
cancer patients undergoing radiotherapy in order to investigate the relationship between
the response to the treatment and the changes in parameters of systemic inflammatory
response.
MATERIALS AND METHODS
Patients
Sixty-one fully diagnosed patients with early disease (stage 1 or 2) underwent thera-
py. Patients with evidence of metastases or concomitant acute infection were excluded
from the study. The patients were diagnosed based on the radiological picture,
bronchoscope and sputum cytology. The clinical diagnosis was confirmed by histopathol-
ogy (squamous cell carcinoma) in all patients. All patients were resectable but inoperable
for medical reasons (i.e., ischemic heart disease or chronic obstructive airway disease) or
unresectable. The patients were treated with curative radiotherapy: 200 cGy/T for five
consecutive days for six weeks (total dose: 6000cGy/T). Clinical assessments were per-
formed before treatment, and after three, six, nine and 12 months ofthe treatment. Serum
samples were collected at the time clinical assessments were done, and stored in a freez-
er (-85°C).
Immunological studies
The IL-6 levels were evaluated using a solid-phase sandwich enzyme-linked-
immuno-sorbent-assay (ELISA). The kits were supplied by BioSource International
(USA). An antibody specific for IL-6 had been coated onto the wells. Samples were pipet-
ted into these wells followed by addition ofbiotinylated second antibody. During the incu-
bation, the antigen (IL-6) binds simultaneously to the capture antibody on one site, and to
the solution phase biotinylated antibody on a second site. After removal of excess second
antibody, streptavidin-peroxidase was added. After removing all of the unbound enzyme,
a substrate solution was added. The intensity ofthis colored product was directly propor-
tional to the concentration of the antigen (IL-6) present in the original specimen. The
lower limit ofdetection of IL-6 was 5 pg/ml. C-reactive protein (CRP) serum levels were
developed using nephelometry methods. Alpha-I acid glycoprotein (AGP) and alpha-I
antichymotrypsin (ACT) were measured using rocket immunoelectrophoresis according
to Laurell [13]. Microheterogeneity ofAGP was employed to differentiate elevation ofIL-
6 and/or CRP induced by acute infection from induced by cancer [14, 15]. It was per-
formed using crossed affinoimmunoelectrophoresis with concanavalin A as a ligand.
Statistical analysis
The Mann-Whitney rank order test was used to evaluate statistical significance.
Relationship between variables was examined using Spearman's correlation coefficient
for continuous variables.
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RESULTS
At the inception of the study the detectable levels of IL-6 were found in majority of
lung cancer patients (49 cases, 80 percent). Table 2 shows the findings ofIL-6 serum level
for individual patients. We did not measure the levels of IL-6 and APP immediately after
radiotherapy, because we expected their nonspecific elevation connected with postradia-
tion tissues damage. After three, six nine and 12 months detectable levels were observed
in 39 of41 (95 percent), 34 of39 (87 percent), 29 of34 (85 percent) and 39 of52 (79 per-
cent) patients respectively. Originally elevated values ofIL-6 decreased during the obser-
vation, however, and we did not find these changes to be statistically significant.
CRP serum levels for individual patient are shown in Table 3. The levels ofCRP, AGP
and ACT were found to be elevated as compared to the control group (Table 1). Twelve
months after the curative radiotherapy we did not notice any statistically significant
changes in the serum level ofAPP. However, we established a correlation between IL-6
and CRP at the beginning ofthe study (r = .638, p < .01) and after 12 months observation
(r = .695, p < .01).
For further analysis we divided our patients into two groups depending on the
response to the treatment. The first group (referred to as responders) comprised 32 patients
with stable disease, partial remission or total remission. Twenty-nine patients with pro-
gression ofthe disease were included to the second group (referred to as non-responders).
The second group included six patients who died due to metastases of the cancer during
the study. The analysis of the new data showed a decrease in IL-6 serum level (Figure 1)
and CRP level (Figure 2) in responders but not in non-responders. Retrospective analysis
of the data obtained from the patients who died due to lung cancer showed a consequent
augmentation of IL-6 and CRP before the patients' death (Figure 3).
DISCUSSION
Lung cancer is a widespread malignant neoplasm among men [16]. Although in
women the incidences of the breast, large bowel and skin cancers are higher, the fatality
rate due to lung cancer is increasing in women, too [16]. Despite progress in recent diag-
nosis and treatment of lung cancer, the death rate remains high. The prognosis for lung
Table 1. The changes in serum levels ofinterleukin-6 (IL-6), C-reactive protein (CRP), alpha-
1 acid glycoprotein (AGP), and alpha-1 antichymotrypsin (ACT) in lung cancer patients
before and after teleradiotherapy.
IL-6 CRP AGP ACT
(pg/ml) (mg/i] [mg/l] [mg/i]
Healthy controls: 9 (<5-17) 5 (<2-11) 0.5 (0.2-0.8) 0.4 (0.1-0.6)
Lung cancer pts:
before treatment 46 (<5-231) 32 (2-102) 1.2 (0.5-3.9) 0.7 (0.2-2.0)
after 3 months 43 (<5-129) 36 (5-99) 1.3 (0.5-4.8) 0.9 (0.3-2.4)
after 6 months 43 (<5-145) 39 (3-112) 1.0 (0.4-3.1) 0.6 (0.2-1.7)
after 9 months 41 (<5-216) 34 (3-95) 0.9 (0.4-3.0) 0.7 (0.2-2.3)
after 12 months 33 (<5-154) 27 (<2-84) 1.2 (0.4-3.4) 0.7 (0.2-1.9)
p < .05 (vs. before treatment)
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Table 2. Serum interleukin-6 levels in individual lung cancer patients.
Patient Sex At the onset After After After After
ofstudy 3 mo 6 mo 9mo 12 mo
Responders
<5
<5
34
<5
<5
<5
<5
<5
<5
<5
<5
9
11
13
18
22
19
30
39
38
50
47
51
56
56
67
68
69
74
89
122
203
<5 <5 <5 <5
<5 <5
26 19
23 11
23 12 10 <5
7 <5 <5 <5
<5 <5 <5 <5
35 <5 9 11
6 8
7 10
15 44 <5
25 29 <5
12 10 6 <5
26 30 85 <5
16
31 14
25 32
33
67 50 30
47 32 14
24 <5 19
53 43 55
19 17
21 <5 22
37 32
66 42 58 22
54 45 34
30 15 12 16
112 56 35 20
22 68 41
87 72 55 78
47
Non-responders
<5
<5
17
23
26
16
110
29
14
84
18
28
43
20
32
65
79
58
163
231
133
8
73
53
8
112
20
31
45
11 40
35 43
15 36
86 49
45 46
24 56
74 55
18 26
57
35
26 33
57
43
129
23
89
48
22
64
57
27
89
145
42
82
115
118
123
36
<5
<5
25 14
18
31 28
58 31
37 30
40
34 35
43 36
31 38
41
48
54 57
40 59
62
44 66
67
107
82 111
154
216 D
157 D
D
D
D
34 30
D
ec m
ks m
kjl m
tm m
hm m
cs m
kg m
mm m
rl m
fs m
sbl m
mb m
ew m
tr m
bz f
wf m
bh m
ti m
fb m
Is m
skl m
aj m
wh m
sh m
wz m
la f
ts m
In m
wc m
wb m
jj m
im m
mw m
hp m
jm m
tg m
bd m
sk2 m
I&g m
kj2 m
bwl f
jj2 m
ws m
sm m
ar m
wa m
wpl m
jz m
as m
sb2 m
wp2 m
mg m
hb f
hk m
ap m
ep m
hw m
gb f
zp m
bs f
bw2 m
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Table 3. Serum C-reactive protein levels in individual lung cancer patients.
Patient Sex At the onset After After After After
of study 3 mo 6 mo 9mo 12 mo
Responders
ec
ks
kjl
tm
hm
Cs
kg
mm
rl
fs
sbl
mb
ew
tr
bz
wf
bh
tl
fb
Is
skl
aj
wh
sh
wz
la
ts
In
wc
wb
ji1
im
mw m
hp m
jm m
tg m
bd m
sk2 m
I& m
kj2 m
bwl f
jj2 m
ws m
sm m
ar m
wa m
wpl m
jz m
as m
sb2 m
wp2 m
mg m
hb f
hk m
ap m
ep m
hw m
gb f
zp m
bs f
bw2 m
m- male, f - female, D - died
m 4 6
m 2
m 82
m 11
m 43 35
m 4 12
m 5 6
m 4 86
m 25
m 12
m 17 7
m 7
m 14 23
m 11 31
f 45
m 53 57
m 14
m 74
m 16 99
m 46 28
m 10 7
m 32 80
m 43 5
m 18 5
m 65
f 27 30
m 56 48
m 3 12
m 39 58
m 34 9
m 61 43
m 75
Non-responders
37
15
45
49
29
S
57
30
12
38
21
39
9
34
35
18
42
37
72
102
47
28
43
19
9
42
41
52
19
6 23
47 70
12 26
48 20
27 68
35 29
24 11
23 31
16
52
36 42
58
64
82
38
44
56
45
60
69
24
45
7 3
6
40 26
15 15
2
22
26 24 3
12 19 9
3 4 12
29 24 23
35 23
39 27
26 17
39 10 3
10 9 3
48 63 31
11
26
45 9
16
76 24
10 30
8 10
21 41
6
25 7
7 6
31 29 18
23 21
4 3 2
42 22 15
31 19
67 49 48
35
47
34
39 26
37
62 35
68 31
31 22
23
51 46
15 9
40 38
47
43
16 52
34 42
19
57 26
84
44
73 66
82
95 D
78 D
D
D
D
48 35
D
112
57
56
84
67
69
40
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Figure 1. The changes in IL-6 serum levels in lung cancer patients undergoing radiotherapy.
A: Responders; B: Non-responders.
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Figure 2. The changes in CRP serum levels in lung cancer patients undergoing radiotherapy.
A: Responders; B: Non-responders.
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Figure 3. The changes in IL-6 and CRP in 6 lung cancer patients who died during the study.
cancer is best ifit is detected in presymptomatic stage, and the treatment is more effective
if we can easily control the changes in the disease progression. Therefore, we are looking
for prognostic markers for better diagnosing and monitoring patients suffering from lung
cancer.
A number ofdifferent laboratory parameters and indices have been already employed
to detect lung cancer progression/remission score. However, none is widely used or has
found universal acceptance as a standard. A group of acute-phase proteins seemed to be
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very promising [17-19]. The evaluation is simple, fast and cheap, but it is very nonspecif-
ic and any infection may produce positive findings. Therefore, cytokines controlling
acute-phase response (APR) became a subject of investigation. IL-6 the main APR acti-
vator has been the most interesting [11, 20].
In the present study we serially evaluated the serum level ofIL-6, CRP, AG andACT.
IL-6 has been found strongly elevated in lung cancer patients and these data are in accor-
dance with the results of others [11, 20, 21]. Moreover, the levels ofAPP were also sig-
nificantly elevated. However, the most interesting results were obtained afterretrospective
analysis of the data of six patients who died during the study period. The levels of IL-6
and CRP increased progressively before the death.
Following the changes in acute-phase response and interleukin-6 serum levels in lung
cancer patients, seems to be helpful in prognosis of the disease. Based on these data, we
suggest that an elevation in IL-6 and/or CRP level in patients with lung cancer may serve
as an adverse prognostic factor. However, it will need further investigation.
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